SecBot SecBot
8-K ·Filed May 19, 2026

VTGN

Vistagen Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed6mo ago SEC0001628280-26-036492
8-K context-dependent: Items 5.02, 7.01
Actionable Insight • Neutral

Routine CMO appointment with no change in business outlook. The inducement stock grant at-the-money signals management's confidence in pipeline progression but creates modest future dilution (~150k shares). Monitor upcoming Phase 3 data readouts for fasedienol (social anxiety disorder) as the primary catalyst for VTGN.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.6400
T+0 close · May 19, 2026 · via day close
Latest settled
−58.19%
T+60 · $0.2676
Vs SPY
−63.19%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 20 $0.6400entry
  2. T+1 · 6mo ago 0.00%α −0.19% · $0.6400
  3. T+5 · 6mo ago −1.56%α −3.36% · $0.6300
  4. T+20 · 5mo ago +4.72%α +3.98% · $0.6702
  5. T+60 · 3mo ago −58.19%α −63.19% · $0.2676

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vistagen appointed Dr. Angel S. Angelov as Chief Medical Officer effective May 18, 2026, with a base salary of $425,000, a $50,000 signing bonus, and an inducement stock option for 150,000 shares at $0.5955/share. This is a routine C-level appointment that fills a key clinical leadership role for a late-stage biopharmaceutical company focused on Phase 3 fasedienol for social anxiety disorder.

Key Facts

  • Appointed Angel S. Angelov, MD, MBA as Chief Medical Officer effective May 18, 2026
  • Annual base salary of $425,000; eligible for annual discretionary cash bonus with initial target of 45% of base salary
  • Received $50,000 signing bonus (50% upon start, 50% at six-month anniversary)
  • Granted inducement stock option to purchase 150,000 shares at $0.5955 per share (closing price on May 18, 2026)
  • Option vests 25% on one-year anniversary, remainder monthly over 36 months; 10-year term
  • Company entered into standard indemnification agreement with Dr. Angelov
  • Dr. Angelov previously served as CMO at Theranica and held VP-level roles at Karuna Therapeutics, Neurocrine Biosciences

Financial Impact

Compensation costs of $425k salary plus $50k signing bonus; option grant of 150k shares represents approximately 1.4% dilution based on $24M market cap and $0.5955 option price (implied shares outstanding ~40M)

dilutionoperating expenses

Risk Factors

  • No new clinical data or pipeline catalysts in this filing
  • Inducement grants add to shareholder dilution over next 4 years
  • Company is pre-revenue clinical-stage with $24M market cap, limited margin for error on Phase 3 trial outcomes

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-036492
Document: vtgn-20260518.htm0001628280-26-036492
Document: vtgn8-kex99120260519.htm0001628280-26-036492
Document: 0001628280-26-036492-index-headers.html0001628280-26-036492
Document: 0001628280-26-036492-index.html0001628280-26-036492
Document: 0001628280-26-036492.txt0001628280-26-036492

Track record

21 reports on VTGN

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +20.40% at T+5 after the Jun 11, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.1843 Now $0.1800 −2.33% settles Nov 24
  2. Nov 13, 20263d ago Press Release Neutral 5/10 Entry $0.1805 Now $0.1800 −0.28% settles Nov 23
  3. Nov 9, 20267d ago 8-K Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
  4. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
  5. Oct 30, 202617d ago 8-K Bearish 6/10 Entry $0.1675 to $0.1844 Now $0.1800 −7.46% ▼ −10.09% −10.01% vs SPY
  6. Oct 9, 20265w ago 8-K Neutral 3/10 Entry $0.2300 to $0.2000 Now $0.1800 −21.74% ▼ −13.04% −11.55% vs SPY
  7. Sep 25, 20267w ago 8-K Neutral 4/10 Entry $0.2700 to $0.2800 Now $0.1800 −33.33% ▲ +3.70% +3.93% vs SPY
  8. Sep 24, 20267w ago 8-K Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
  9. Sep 24, 20267w ago Press Release Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
  10. Aug 14, 202613w ago 8-K Bearish 6/10 No price data
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 19, 2026